John Varian Joins Acorda Therapeutics Board of Directors
04 January 2022 - 8:01AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that
John Varian has joined its board of directors, effective January 1,
2022.
“We are delighted that John has joined Acorda’s board of
directors,” said Ron Cohen, M.D., Acorda’s President and Chief
Executive Officer. “We expect his insights and counsel to
contribute significantly as we continue to make progress on our
corporate goals, including optimizing the company’s financial
structure and accelerating the growth of INBRIJA.”
“I look to serve on Boards of companies that represent
significant opportunities, as well as challenges where my
experience and skill sets can be helpful. Acorda is such a company,
and I am excited to be joining the Board,” said Mr. Varian. “Acorda
has two important products on the market, one for Parkinson’s
disease and one for multiple sclerosis. I’m impressed by the
progress they have made in 2021 in addressing the company’s
challenges, and I look forward to helping build on this progress in
2022 and beyond.”
John Kelley, Acorda’s Board Chair, added: “I welcome John, on
behalf of Acorda’s Board. John has extensive experience as a
biopharma leader, including as both a CFO and CEO. He has
successfully managed challenges similar to those that Acorda is
addressing, and we look forward to working with him to build
shareholder value”.
Mr. Varian currently serves on the board of directors for AmMax
Bio and for Sellas Life Sciences, where he is Chair of the Audit
Committee and on its Nominating and Goverance Committee and Science
Committee. Previously, he was the Chief Executive Officer of XOMA
Corporation, where he led a financial restructuring of the company
and also served on its Board of Directors. Mr. Varian previously
held roles as Chief Operating Officer of ARYx Therapeutics, Inc.,
Chief Financial Officer of Genset S.A., and as Senior Vice
President, Finance and Administration for Elan Pharmaceuticals,
Inc. Mr. Varian also served as a member of the Board of Directors
of Versartis, Inc. and Egalet Corporation.
About Acorda Therapeutics Acorda Therapeutics develops
therapies to restore function and improve the lives of people with
neurological disorders. INBRIJA® is approved for intermittent
treatment of OFF episodes in adults with Parkinson’s disease
treated with carbidopa/levodopa. INBRIJA is not to be used by
patients who take or have taken a nonselective monoamine oxidase
inhibitor such as phenelzine or tranylcypromine within the last two
weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary
delivery system, a technology platform designed to deliver
medication through inhalation. Acorda also markets the branded
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Forward-Looking Statements This press release includes
forward-looking statements. All statements, other than statements
of historical facts, regarding management's expectations, beliefs,
goals, plans or prospects should be considered forward-looking.
These statements are subject to risks and uncertainties that could
cause actual results to differ materially, including: we may not be
able to successfully market AMPYRA, INBRIJA or any other products
under development; the COVID-19 pandemic, including related
restrictions on in-person interactions and travel, and the
potential for illness, quarantines and vaccine mandates to affect
our management, employees or consultants or those that work for
other companies we rely upon, could have a material adverse effect
on our business operations or product sales; our ability to attract
and retain key management and other personnel, or maintain access
to expert advisors; our ability to raise additional funds to
finance our operations, repay outstanding indebtedness or satisfy
other obligations, and our ability to control our costs or reduce
planned expenditures; risks associated with the trading of our
common stock and our reverse stock split; risks related to our
corporate restructurings, including our ability to outsource
certain operations, realize expected cost savings and maintain the
workforce needed for continued operations; risks associated with
complex, regulated manufacturing processes for pharmaceuticals,
which could affect whether we have sufficient commercial supply of
INBRIJA to meet market demand; our reliance on third-party
manufacturers for the production of commercial supplies of AMPYRA
and INBRIJA; third-party payers (including governmental agencies)
may not reimburse for the use of INBRIJA at acceptable rates or at
all and may impose restrictive prior authorization requirements
that limit or block prescriptions; reliance on collaborators and
distributors to commercialize INBRIJA and AMPYRA outside the U.S.;
competition for INBRIJA and AMPYRA, including increasing
competition and accompanying loss of revenues in the U.S. from
generic versions of AMPYRA (dalfampridine) following our loss of
patent exclusivity; the ability to realize the benefits anticipated
from acquisitions, among other reasons because acquired development
programs are generally subject to all the risks inherent in the
drug development process and our knowledge of the risks
specifically relevant to acquired programs generally improves over
time; the risk of unfavorable results from future studies of
INBRIJA (levodopa inhalation powder) or from other research and
development programs, or any other acquired or in-licensed
programs; the occurrence of adverse safety events with our
products; the outcome (by judgment or settlement) and costs of
legal, administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class-action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third-party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220103005373/en/
Tierney Saccavino (914) 326-5104 tsaccavino@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024